|Bid||198.00 x 900|
|Ask||200.25 x 1000|
|Day's range||200.28 - 203.71|
|52-week range||141.41 - 249.27|
|Beta (5Y monthly)||0.66|
|PE ratio (TTM)||48.28|
|Earnings date||15 Feb 2022|
|Forward dividend & yield||1.30 (0.65%)|
|Ex-dividend date||19 Jan 2022|
|1y target est||248.83|
Let's look at two excellent companies that could turn $250,000 into $1,000,000 -- that's a compound annual growth rate of 14.87% -- in the next 10 years: Zoetis (NYSE: ZTS) and Spotify (NYSE: SPOT). Zoetis is one of the leading animal health companies in the world. Zoetis boasts 13 products that generate $100 million or more in annual revenue, and its financial results continue to impress.
PARSIPPANY, N.J., January 13, 2022--Zoetis today announced that the U.S. Food and Drug Administration (FDA) has approved Solensia™ to control the pain of osteoarthritis (OA) in cats.
Shares of Zoetis (NYSE: ZTS) had a strong 2021 as the animal health company posted solid growth throughout the year and consistently raised its guidance. Zoetis shares slumped through the first two months of the year as a solid fourth-quarter 2020 earnings report wasn't enough to give the stock a boost.